SecBot SecBot
SECBOTREPLAY Home › Report › MRNA

MRNA · Wolfe Research double-upgraded MRNA from Underperform to Peer Perform…

Moderna, Inc. · ANALYST-UPGRADE filed Aug 25, 2026 at 10:28 ET

At the news

MIXEDIMPACT 1/10

ANALYST-UPGRADE filed Aug 25, 2026 at 10:28 ET

Wolfe Research double-upgraded MRNA from Underperform to Peer Perform on August 25, 2026, a notable shift from a bearish stance to a neutral-equivalent rating. The firm's track record is average at 52% accuracy on 451 calls with a 4.4% average return. Consensus on MRNA is heavily tilted toward the sidelines: 30% Buy (9 of 30), 60% Hold (18), and 10% Sell (3). The mean price target of $95.67 implies 31% downside from the current $138.89, while the median of $83 suggests deeper downside. Momentum is mixed, 2 upgrades in 30 days (including this one) and 0 downgrades, but EPS revisions for the current fiscal year show 13 upward revisions vs 5 downward, a net positive. Insider selling is significant: CEO Stephane Bancel sold $28.7M worth on August 5, and the CFO sold $3.6M in July, creating a bearish divergence with the upgrade. Short interest is elevated at 62.3% of float, indicating heavy bearish positioning. The bottom line: this is a low-conviction upgrade from an average-accuracy firm, partially offset by improving EPS revisions, but heavy insider selling and a bearish consensus cap the upside.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access